LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

Search

Charles River Laboratories International Inc

Gesloten

SectorGezondheidszorg

168.66 -1.6

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

167.72

Max

174.52

Belangrijke statistieken

By Trading Economics

Inkomsten

2.9M

56M

Verkoop

-27M

1B

K/W

Sectorgemiddelde

592.3

105.69

EPS

2.43

Winstmarge

5.529

Werknemers

18,700

EBITDA

-23M

198M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+11.95% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-487M

8.3B

Vorige openingsprijs

170.26

Vorige sluitingsprijs

168.66

Nieuwssentiment

By Acuity

21%

79%

49 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

Charles River Laboratories International Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 nov 2025, 21:34 UTC

Winsten

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

13 nov 2025, 23:45 UTC

Marktinformatie

Nikkei May Fall After Wall Street's Weakness -- Market Talk

13 nov 2025, 23:42 UTC

Acquisities, Fusies, Overnames

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

13 nov 2025, 23:41 UTC

Marktinformatie

Gold Edges Higher on Possible Dip-Buying -- Market Talk

13 nov 2025, 23:24 UTC

Winsten

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

13 nov 2025, 23:24 UTC

Winsten

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

13 nov 2025, 23:23 UTC

Winsten

JBS NV 3Q EPS 52c >JBS

13 nov 2025, 23:23 UTC

Winsten

JBS NV 3Q Sales $22.6B >JBS

13 nov 2025, 23:04 UTC

Marktinformatie

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

13 nov 2025, 22:02 UTC

Winsten

Nu Holdings 3Q Net $783M >NU

13 nov 2025, 22:01 UTC

Winsten

Nu Holdings 3Q Rev $4.2B >NU

13 nov 2025, 21:51 UTC

Acquisities, Fusies, Overnames

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

13 nov 2025, 21:50 UTC

Winsten

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

13 nov 2025, 21:45 UTC

Acquisities, Fusies, Overnames

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

13 nov 2025, 21:41 UTC

Acquisities, Fusies, Overnames

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

13 nov 2025, 21:36 UTC

Acquisities, Fusies, Overnames

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

13 nov 2025, 21:36 UTC

Acquisities, Fusies, Overnames

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

13 nov 2025, 21:36 UTC

Acquisities, Fusies, Overnames

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

13 nov 2025, 21:36 UTC

Acquisities, Fusies, Overnames

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

13 nov 2025, 21:36 UTC

Acquisities, Fusies, Overnames

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

13 nov 2025, 21:33 UTC

Marktinformatie

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

13 nov 2025, 21:33 UTC

Winsten

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

13 nov 2025, 21:31 UTC

Winsten

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

13 nov 2025, 21:25 UTC

Winsten

Figure Tech Solutions 3Q Rev $156.4M >FIGR

13 nov 2025, 21:25 UTC

Winsten

Figure Tech Solutions 3Q EPS 34c >FIGR

13 nov 2025, 21:23 UTC

Winsten

Intchains Group 3Q Rev $1.3M >ICG

13 nov 2025, 21:03 UTC

Winsten

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

13 nov 2025, 21:02 UTC

Winsten

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

13 nov 2025, 21:01 UTC

Winsten

Applied Materials 4Q Rev $6.8B >AMAT

13 nov 2025, 21:01 UTC

Winsten

Applied Materials 4Q Gross Margin 48.0% >AMAT

Peer Vergelijking

Prijswijziging

Charles River Laboratories International Inc Prognose

Koersdoel

By TipRanks

11.95% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 192 USD  11.95%

Hoogste 225 USD

Laagste 165 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Charles River Laboratories International Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

12 ratings

6

Buy

6

Hold

0

Sell

Technische score

By Trading Central

117.16 / 144.77Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

49 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat